Journal
ORGANIC PROCESS RESEARCH & DEVELOPMENT
Volume 26, Issue 10, Pages 2926-2936Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.oprd.2c00242
Keywords
KRAS; oncogene; metalation; quinazoline; Knochel-Hauser base
Categories
Ask authors/readers for more resources
ARS-1620, a quinazoline compound, is a mutant-specific covalent inhibitor of KRAS(G12C) that has recently been discovered. A novel synthetic approach involving metalation at C7 position of substituted quinazolines has been developed for the multigram production of ARS-1620. The metalation process has shown excellent selectivity, enabling the scalable synthesis of kilogram quantities of compounds in this family and accelerating medicinal chemistry efforts.
The quinazoline compound ARS-1620 is a recently discovered, mutant-specific covalent inhibitor of KRAS(G12C). Route scouting in support of multigram ARS-1620 batches led to a new synthetic approach that relies on metalation of substituted quinazolines at C7. The exquisite selectivity seen in this metalation formed the basis for a scalable route to kilogram quantities of compounds in this family. It also accelerated medicinal chemistry efforts as critical intermediates became readily available in large quantities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available